Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   OpGen   /   Curetis-OpGen - 2020: wordt het nog wat..?

Aandeel OpGen OTC:OPGN.Q, US68373L5057

Vertraagde koers (usd) Verschil Volume
1,960   0,000   (0,00%) Dagrange 0,000 - 0,000 0  

Curetis-OpGen - 2020: wordt het nog wat..?

Volgen
2.575 Posts
Pagina: «« 1 ... 113 114 115 116 117 ... 129 »» | Laatste | Omlaag ↓
  2. forum rang 10 DeZwarteRidder 8 mei 2020 08:37

    OpGen Reports First Quarter 2020 Financial Results and Provides Business Update
    05.07.20
    Download PDF

    Total Revenue for Q1 2020 was approximately $617,000 (excluding Curetis Revenue)
    Curetis and Ares revenue was approximately $900,000 for the first quarter generating a pro forma combined unaudited revenue of over $1.5 million
    Balance sheet strengthened significantly with $13.9 million cash raised in Q1 2020
    OpGen and Curetis successfully completed business combination effective April 1, 2020
    Multiple shipments of BGI SARS-CoV-2 rapid PCR kits completed by Curetis in Europe. Additional actions planned to address the global COVID-19 pandemic

    Conference call to be held at 4:30 p.m. Eastern Time today

    GAITHERSBURG, Md., May 07, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, reported today its stand-alone financial and operating results for the three months ended March 31, 2020 and provided a business update. Total OpGen revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019. Revenue from Curetis and Ares, OpGen’s wholly owned subsidiaries, was approximately $900,000 for the first quarter generating a pro-forma combined unaudited revenue of over $1.5 million. OpGen’s cash as of March 31, 2020 was approximately $11.5 million, up significantly from the $2.7 million as of December 31, 2019. This amount did not include the approximately $900,000 in cash held by Curetis and Ares at March 31, 2020.

    Oliver Schacht, President and CEO of OpGen commented, “Despite the unprecedented global crisis situation with COVID-19, we are pleased with our first quarter results and remain confident in the strength of our 2020 pipeline. We acknowledge that this is an ever-changing situation and are prepared to mitigate any further potential impact that COVID-19 might have on our global operations. We would like to reassure you that as a company we are resilient and OpGen with its subsidiaries Curetis and Ares Genetics boasts a strong proprietary product portfolio that is extremely agile, flexible and has elements in place to rapidly identity, develop and create potential offerings needed to address future infectious disease outbreaks.”

    Mr. Schacht continued, “We expect the CoV-2 rapid PCR test kit sales in Europe to continue contributing positively to our top-line revenue in Q2 of 2020. Since mid-March 2020, we sold approximately 15,000 CoV-2 tests into our distribution network. Additionally, we recently announced our collaboration with Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections. Due to the nature of the CoV-2 virus, we believe it is crucial to be able to rapidly detect a comprehensive spectrum of bacterial and fungal pathogens and antibiotic resistance markers in lower respiratory tract specimens that could be a critical factor in saving patients lives during the ongoing pandemic. The study has already started and we expect to see initial results in the coming weeks.”

  3. forum rang 10 DeZwarteRidder 8 mei 2020 08:37
    First Quarter 2020 Financial Results of OpGen, Inc. Stand-alone

    Total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019. This decrease can be attributed to Acuitas AMR Gene Panel and Acuitas® Lighthouse revenue, which was approximately $254,000, while revenues from the company’s rapid FISH products decreased to $363,000. Curetis and Ares revenue was approximately $900,000 for the first quarter generating a pro forma combined unaudited revenue of over $1.5 million.
    Operating expenses for the first quarter of 2020 were $4.6 million, compared with $4.8 million in the first quarter of 2019.
    The net loss for the first quarter of 2020 was $3.9 million or $0.53 per share, compared with $3.9 million or $8.25 per share in the first quarter of 2019.

    The Company also provided the following business updates that were achieved during the first quarter of 2020:

    Successful closure of the business combination between OpGen and Curetis on April 1, 2020. At the closing, William E. Rhodes III, the former chairman of the Supervisory Board of Curetis N.V., was appointed chairman of the board of OpGen, and Oliver Schacht, Ph.D., the former Chief Executive Officer of Curetis N.V., was appointed the President and Chief Executive Officer of OpGen and to the board of directors;
    The newly formed board of directors of OpGen now also includes Evan Jones, former Chairman and CEO of OpGen, Don Elsey, Mario Crovetto, and Prabhavathi Fernandes, PhD;
    Announced the start of an investigator initiated collaboration with Karolinska Institutet, Sweden, to identify bacterial co-infections in patients admitted to the ICU for COVID-19 pneumonia using the Unyvero HPN panel;
    OpGen significantly improved its working capital position in the first quarter of 2020 through $5.8 million of sales under the company’s ATM program and $8.1 million in proceeds from the exercise of warrants issued in the company’s public offering in October 2019;
    Clinical trials were initiated during the first quarter of 2020 at nine participating sites for the Acuitas AMR Gene Panel (Urine) test. Testing and the trial have been suspended due to hospital actions to focus resources on the COVID-19 pandemic;
    Acuitas Lighthouse® was utilized in a research study conducted by the Mayo Clinic to predict phenotypic resistance and antimicrobial susceptibility among clinical isolates, with findings published in Diagnostic Microbiology & Infectious Disease; and
    Curetis, Ares Genetics, and BGI announced a partnership around BGI’s CoV-2 test kit commercialization in Europe; Curetis has begun selling the BGI CoV-2 product via its distribution network in EMEA during Q1 2020 and to date has sold over 15,000 tests into its distribution network.

    Additional key business updates and strategic milestones include:

    OpGen’ expects that its submission to the U.S. Food and Drug Administration (“FDA”) for clearance of the Acuitas® AMR Gene Panel (Isolates) for the detection of antimicrobial resistance genes in bacterial isolates is nearing completion. OpGen has responded, and is continuing to respond, to the FDA’s additional information requests and now anticipates approaching a clearance decision for the Acuitas® AMR Gene Panel for isolates. Exact timing is unknown as a result of the COVID-19 pandemic;
    OpGen successfully achieved the last of the first year milestones in the groundbreaking collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide. In response to the COVID-19 emergency in New York State, testing under the program has been put on hold by the Wadsworth Center and participating hospitals; however, the parties are currently engaged in active negotiations and discussions for a second year of the collaboration and expect to resume the project and expand it into its second year once the COVID-19 situation permits;
    OpGen’s subsidiary Ares Genetics in April announced that a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS) has been pre-published in the Journal of Clinical Microbiology. The study was performed by Ares Genetics GmbH and Curetis GmbH, and scientists at the Max Perutz Labs (Austria), a joint venture of the University of Vienna and the Medical University of Vienna, and the Mayo Clinic (Rochester, MN, U.S.A.); and
    Curetis and Quaphaco entered into an exclusive three-year distribution partnership for the Unyvero product line in Vietnam; the contract includes minimum commitments by Quaphaco totaling approximately $ 2.1 million over the initial three-year term.

    Mr. Schacht continued, “We have a strong pipeline heading into the second quarter of 2020 despite the unique market challenges presented at this time. With the anticipated near term FDA clearance decision and subsequent launch of our Acuitas AMR Gene Panel product for isolate and the exciting combination of the Acuitas Lighthouse® database with the ARESdb, our strong, proprietary product pipeline attests to our ability to deliver premier AI-powered bioinformatics solutions and diagnostic products. We are especially excited about an upcoming major milestone in the Ares collaboration with its strategic R&D collaboration partner, a leading global IVD corporation, where completion of the R&D phase is expected for the third quarter this year. The IVD corporate partner has pre-funded an option which upon exercise would then grant it 90 days of exclusive negotiations with Ares regarding a potential future partnering and licensing deal.”
  4. forum rang 10 DeZwarteRidder 8 mei 2020 08:39
    First Quarter 2020 Financial Results of OpGen, Inc. Stand-alone

    Total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019. This decrease can be attributed to Acuitas AMR Gene Panel and Acuitas® Lighthouse revenue, which was approximately $254,000, while revenues from the company’s rapid FISH products decreased to $363,000.

    Curetis and Ares revenue was approximately $900,000 for the first quarter generating a pro forma combined unaudited revenue of over $1.5 million.
    Operating expenses for the first quarter of 2020 were $4.6 million, compared with $4.8 million in the first quarter of 2019.
    The net loss for the first quarter of 2020 was $3.9 million or $0.53 per share, compared with $3.9 million or $8.25 per share in the first quarter of 2019.
  5. forum rang 10 DeZwarteRidder 8 mei 2020 08:42
    quote:

    DeZwarteRidder schreef op 8 mei 2020 08:39:

    First Quarter 2020 Financial Results of OpGen, Inc. Stand-alone

    Total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019. This decrease can be attributed to Acuitas AMR Gene Panel and Acuitas® Lighthouse revenue, which was approximately $254,000, while revenues from the company’s rapid FISH products decreased to $363,000.

    Curetis and Ares revenue was approximately $900,000 for the first quarter generating a pro forma combined unaudited revenue of over $1.5 million.
    Operating expenses for the first quarter of 2020 were $4.6 million, compared with $4.8 million in the first quarter of 2019.
    The net loss for the first quarter of 2020 was $3.9 million or $0.53 per share, compared with $3.9 million or $8.25 per share in the first quarter of 2019.
    Dus het verlies van Curetis zit hier nog niet in.....!!!!

    De volgende emissie zit er weer aan te komen.
  7. forum rang 4 Pitmans 8 mei 2020 10:13
    Kasreserve op 31 maart was $12,5 miljoen. Bij een jaarverlies van $30 miljoen, kunnen ze dus minder dan een half jaar vooruit.

    En 15000 coronatesten gaan dat gat niet opvullen.
    De cijfers wijken nauwelijks af van wat werd besproken in de concall die over de Q4-cijfers die op 23 maart werd gehouden. Daarin was wat betreft die coronatesten sprake van "We've gone from, let's say, low single-digit thousands. Our second order, which we received yesterday, is the first 5-digit number of tests"
    Als de nieuwe update daadwerkelijk alleen Q1 beslaat, klopt dat cijfer dus wel, maar is het wel de meest minimale realisatie die mogelijk was. Ik heb de concall gisteren niet gevolgd, maar ik vrees dat ook dit ballonetje weer geen groot succes is (nog afgezien van de minimale marges die curetis/opgen er aan overhoudt per test). Anders was het vast wel meegenomen in het PB.

    Oproepje aan curetis aandeelhouders die de stukken aangehouden hebben : laat even weten of je inmiddels de opgen-stukken in je porto hebt.
    Ben wel benieuwd of dat ordelijk is verlopen namelijk.
  8. forum rang 10 DeZwarteRidder 8 mei 2020 10:50
    quote:

    Pitmans schreef op 8 mei 2020 10:13:

    Kasreserve op 31 maart was $12,5 miljoen. Bij een jaarverlies van $30 miljoen, kunnen ze dus minder dan een half jaar vooruit.

    En 15000 coronatesten gaan dat gat niet opvullen.
    De cijfers wijken nauwelijks af van wat werd besproken in de concall die over de Q4-cijfers die op 23 maart werd gehouden. Daarin was wat betreft die coronatesten sprake van "We've gone from, let's say, low single-digit thousands. Our second order, which we received yesterday, is the first 5-digit number of tests"
    Als de nieuwe update daadwerkelijk alleen Q1 beslaat, klopt dat cijfer dus wel, maar is het wel de meest minimale realisatie die mogelijk was. Ik heb de concall gisteren niet gevolgd, maar ik vrees dat ook dit ballonetje weer geen groot succes is (nog afgezien van de minimale marges die curetis/opgen er aan overhoudt per test). Anders was het vast wel meegenomen in het PB.

    Oproepje aan curetis aandeelhouders die de stukken aangehouden hebben : laat even weten of je inmiddels de opgen-stukken in je porto hebt.
    Ben wel benieuwd of dat ordelijk is verlopen namelijk.
    Op het Duitse forum wordt geklaagd dat ze nog niks gekregen hebben, maar dat komt heus nog wel in orde.
  9. forum rang 10 DeZwarteRidder 8 mei 2020 10:53
    quote:

    DeZwarteRidder schreef op 8 mei 2020 08:39:

    First Quarter 2020 Financial Results of OpGen, Inc. Stand-alone

    Total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019. This decrease can be attributed to Acuitas AMR Gene Panel and Acuitas® Lighthouse revenue, which was approximately $254,000, while revenues from the company’s rapid FISH products decreased to $363,000.

    Curetis and Ares revenue was approximately $900,000 for the first quarter generating a pro forma combined unaudited revenue of over $1.5 million.
    Operating expenses for the first quarter of 2020 were $4.6 million, compared with $4.8 million in the first quarter of 2019.
    The net loss for the first quarter of 2020 was $3.9 million or $0.53 per share, compared with $3.9 million or $8.25 per share in the first quarter of 2019.
    Het kwartaalverlies van Curetis schat ik op ca 5 tot 6 miljoen. In totaal wordt dit dan ca 10 miljoen verlies per kwartaal.
2.575 Posts
Pagina: «« 1 ... 113 114 115 116 117 ... 129 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee